Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 271 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination Clear all
Completed Phase 3 Interventional

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

NCT05603832
View directory record Official record
Conditions
Post Operative Pain
Interventions
F14, 0.25 % Bupivacaine HCl, Acetaminophen, Methocarbamol
Drug
Lead sponsor
Arthritis Innovation Corporation
Industry
Eligibility
45 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • Tamarac, Florida • Tulsa, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control

NCT01916590
View directory record Official record
Conditions
Post-operative Pain
Interventions
Bupivicaine, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty

NCT04591353
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
PENG Block, Lidocaine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

NCT04849858
View directory record Official record
Conditions
Ovarian Cancer, Fibroids, Uterine Cancer
Interventions
Bupivacaine, Liposomal bupivacaine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT05456490
View directory record Official record
Conditions
Healthy
Interventions
Liposomal Bupivacaine 13.3, Bupivacaine, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy

NCT04073056
View directory record Official record
Conditions
Morbid Obesity, High BMI
Interventions
Bupivacaine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 9:14 AM EDT
Not listed Not applicable Interventional

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

NCT05276258
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
cryoSPHERE Ablation, Bupivacaine
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 9, 2026, 9:14 AM EDT
Withdrawn Phase 4 Interventional

EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

NCT03955458
View directory record Official record
Conditions
Hip Fractures, Intertrochanteric Fractures
Interventions
EXPAREL, Ropivacaine, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
65 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial for Exparel Hip Fracture

NCT03289858
View directory record Official record
Conditions
Hip Fractures
Interventions
Exparel, Sodium Chloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
55 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures

NCT02604589
View directory record Official record
Conditions
Rib Fractures
Interventions
hydromorphone hydrochloride, Infusion catheter placement, bupivicaine 0.25%, bupivicaine 0.5%
Drug · Procedure
Lead sponsor
Anthony Iacco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients

NCT03682224
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer Stage 1
Interventions
Liposomal Bupivacaine, Bupivacaine-Epinephrine
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Open-Label CA-008 (Vocacapsaicin) in Bunionectomy

NCT03885596
View directory record Official record
Conditions
Pain
Interventions
CA-008, Ketorolac, Acetaminophen IV, Fentanyl, Bupivacaine Hydrochloride, Lidocaine HCl, Celecoxib, Acetaminophen Oral, Lidocaine Hydrochloride, Exparel
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 9, 2026, 9:14 AM EDT
Not listed Phase 2 Interventional

Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction

NCT02913573
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Ultrasound, 0.25% bupivacaine
Device · Drug
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional Results available

0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka

NCT03303794
View directory record Official record
Conditions
Anesthesia
Interventions
Exparel, 0.25% bupivacaine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks

NCT03708198
View directory record Official record
Conditions
Thoracic
Interventions
Liposomal Bupivacaine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Results available

Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations

NCT05140499
View directory record Official record
Conditions
Pain, Postoperative, Amputation
Interventions
Liposomal bupivacaine, Bupivacaine Hydrochloride 0.5 % Injectable Solution
Drug
Lead sponsor
Aurora Quaye
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional Results available

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions
Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine with adjuvants
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03682302
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
Exparel, 0.5% Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
17
States / cities
Loma Linda, California • Sacramento, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery

NCT04393207
View directory record Official record
Conditions
Opioid Use, Pain, Acute
Interventions
Liposomal bupivacaine (LB), Dexamethasone and methylprednisolone (CG), Control group (Bupivacaine)- (BPG)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 9, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional Results available

Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair

NCT02075411
View directory record Official record
Conditions
Injury of Anterior Cruciate Ligament
Interventions
bupivacaine, continuous perineural infusion catheter
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Early Phase 1 Interventional

Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?

NCT02740192
View directory record Official record
Conditions
Pain
Interventions
Adductor Canal Block, Periarticular Injection, Ropivacaine, Bupivacaine
Procedure · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
View directory record Official record
Conditions
C-Section, Pain Management
Interventions
Exparel + Bupivacaine, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 9, 2026, 9:14 AM EDT
Completed Phase 2 Interventional

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

NCT03541655
View directory record Official record
Conditions
Total Knee Replacement, Postoperative Pain
Interventions
Bupivacaine HCl, F14 (celecoxib)
Drug
Lead sponsor
Arthritis Innovation Corporation
Industry
Eligibility
45 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Dayton, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 9, 2026, 9:14 AM EDT